{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:28:30Z","timestamp":1788222510474,"version":"build-2803163510"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although high-grade salivary gland cancers (SGCs) often express androgen receptor (AR) and\/or HER-2\/neu, therapeutically targeting these receptors in SGC remains investigational. We investigated the prevalence of receptor expression and the benefit of adjuvant HER-2 directed therapy in the high-risk postoperative setting and explored the clinical utility of sequentially targeting these receptors in the setting of advanced disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We clinically annotated 95 patients with SGC (excluding adenoid cystic carcinoma) treated at our institution from 2002 to 2019 and recorded AR, HER-2\/neu status, and tumor genomic profiling results when available. Clinicopathologic information was then integrated with outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 95 patients, most had high-risk histologies, with salivary duct carcinoma (SDC) as the most frequent diagnosis (43, 45%). Thirty-five (37%) experienced recurrence (51% SDC). HER-2\/neu was positive (1\u20133+) by immunostaining in 34 of 52 (65%) evaluable cases. There was no difference in survival based on HER-2\/neu or AR expression. Nine of 17 (53%) patients with HER-2+ SDC received adjuvant chemoradiation with trastuzumab. Median disease-free survival (DFS) and overall survival (OS) were longer among patients with HER-2\/neu 3+ staining tumors who received adjuvant trastuzumab versus those who did not (DFS, 117 vs. 9 months; p = .02; OS, 74 vs. 43 months; p = .02), with no difference among other HER-2\/neu subgroups (0\u20132+). Two of nine (22%) patients treated with adjuvant trastuzumab demonstrated recurrence, both with low HER-2\/neu staining intensity (1+). Longer time to recurrence (hazard ratio, 0.94; p = .01) predicted improved outcomes. Both androgen deprivation and HER-2-directed therapies had clinical benefit beyond the first-line metastatic setting, with partial response observed beyond second-line use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Although prospective data are lacking, the use of adjuvant trastuzumab in high-risk patients with SGC appears beneficial, particularly among patients with tumors exhibiting HER-2\/neu 3+ immunostaining.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Results of this study showed an improved disease-free and overall survival in patients treated with adjuvant trastuzumab for high-risk salivary gland cancers with strong HER-2\/neu staining intensity. Following recurrence or metastatic spread, sequential HER-2, and androgen-directed therapies may benefit certain patients with salivary gland cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0841","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T13:41:41Z","timestamp":1587390101000},"page":"598-608","source":"Crossref","is-referenced-by-count":35,"title":["The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers"],"prefix":"10.1093","volume":"25","author":[{"given":"Glenn J.","family":"Hanna","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen H.","family":"Lorch","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie Y.","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle N.","family":"Margalit","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy B.","family":"Tishler","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Goguen","sequence":"additional","affiliation":[{"name":"Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Division of Otolaryngology-Head and Neck Surgery, Brigham & Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Donald J.","family":"Annino","sequence":"additional","affiliation":[{"name":"Head and Neck Surgical Oncology, Dana-Farber Cancer Institute, Division of Otolaryngology-Head and Neck Surgery, Brigham & Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole G.","family":"Chau","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"BC Cancer, Vancouver Centre, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"key":"2021122510440555400_onco13297-bib-0001","doi-asserted-by":"crossref","first-page":"25631","DOI":"10.18632\/oncotarget.4554","article-title":"Genomic landscape of salivary gland tumors","volume":"6","author":"Kato","year":"2015","journal-title":"Oncotarget"},{"key":"2021122510440555400_onco13297-bib-0002","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/modpathol.3880525","article-title":"Salivary gland neoplasia: A review for the practicing pathologist","volume":"15","author":"Zarbo","year":"2002","journal-title":"Mod Pathol"},{"key":"2021122510440555400_onco13297-bib-0003","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.adro.2017.03.008","article-title":"Adjuvant radiation for salivary gland malignancies is associated with improved survival: A National Cancer Database analysis","volume":"2","author":"Bakst","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"2021122510440555400_onco13297-bib-0004","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1177\/0194599817717661","article-title":"Impact of adjuvant radiotherapy for malignant salivary gland tumors","volume":"157","author":"Safdieh","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2021122510440555400_onco13297-bib-0005","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jamaoto.2016.2168","article-title":"Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: Data From the National Cancer Data Base","volume":"142","author":"Amini","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2021122510440555400_onco13297-bib-0006","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hed.24984","article-title":"Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database","volume":"40","author":"Cheraghlou","year":"2018","journal-title":"Head Neck"},{"key":"2021122510440555400_onco13297-bib-0007","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122510440555400_onco13297-bib-0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12105-017-0833-y","article-title":"Expression of hormone receptors and HER-2 in benign and malignant salivary gland tumors","volume":"12","author":"Can","year":"2018","journal-title":"Head Neck Pathol"},{"key":"2021122510440555400_onco13297-bib-0009","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/1078-0432.CCR-03-0253","article-title":"HER2 expression in salivary gland carcinomas: Dependence on histological subtype","volume":"10","author":"Glisson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122510440555400_onco13297-bib-0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.humpath.2019.08.007","article-title":"Androgen receptor immunohistochemistry in salivary duct carcinoma: A retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance","volume":"17","author":"Xu","year":"2019","journal-title":"Hum Pathol"},{"key":"2021122510440555400_onco13297-bib-0011","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/PAT.0b013e3283484a60","article-title":"Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas","volume":"43","author":"Clauditz","year":"2011","journal-title":"Pathology"},{"key":"2021122510440555400_onco13297-bib-0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"110","author":"van Boxtel","year":"2019","journal-title":"Eur J Cancer"},{"key":"2021122510440555400_onco13297-bib-0013","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"The Oncologist"},{"key":"2021122510440555400_onco13297-bib-0014","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122510440555400_onco13297-bib-0015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"issue":"suppl","key":"2021122510440555400_onco13297-bib-0016","doi-asserted-by":"crossref","first-page":"6020a","DOI":"10.1200\/JCO.2019.37.15_suppl.6020","article-title":"Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers","volume":"37","author":"Ho","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122510440555400_onco13297-bib-0017","first-page":"v372","article-title":"Phase II trial of abiraterone acetate in patients with relapsed and\/or metastatic, castration resistant AR expressing salivary glands carcinomas (SGCs)","volume":"28","author":"Locati","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122510440555400_onco13297-bib-0018","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"issue":"suppl","key":"2021122510440555400_onco13297-bib-0019","doi-asserted-by":"crossref","first-page":"6001a","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510440555400_onco13297-bib-0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510440555400_onco13297-bib-0021","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510440555400_onco13297-bib-0022","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122510440555400_onco13297-bib-0023","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"2021122510440555400_onco13297-bib-0024","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: A targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2021122510440555400_onco13297-bib-0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122510440555400_onco13297-bib-0026","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"key":"2021122510440555400_onco13297-bib-0027","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann Oncol"},{"key":"2021122510440555400_onco13297-bib-0028","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-15-2568","article-title":"Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122510440555400_onco13297-bib-0029","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1002\/cncr.22647","article-title":"Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland","volume":"109","author":"Carrillo","year":"2007","journal-title":"Cancer"},{"key":"2021122510440555400_onco13297-bib-0030","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1097\/00005537-200108000-00021","article-title":"Prognostic factors in major salivary gland cancer","volume":"111","author":"Hocwald","year":"2011","journal-title":"Laryngoscope"},{"key":"2021122510440555400_onco13297-bib-0031","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2255::AID-CNCR22>3.0.CO;2-D","article-title":"Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors","volume":"85","author":"Vander Poorten","year":"1999","journal-title":"Cancer"},{"key":"2021122510440555400_onco13297-bib-0032","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jamaoto.2015.3930","article-title":"A 20-year review of 75 cases of salivary duct carcinoma","volume":"142","author":"Gilbert","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2021122510440555400_onco13297-bib-0033","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.31353","article-title":"A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands","volume":"143","author":"Boon","year":"2018","journal-title":"Int J Cancer"},{"key":"2021122510440555400_onco13297-bib-0034","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122510440555400_onco13297-bib-0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10147-014-0674-6","article-title":"Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma","volume":"20","author":"Masubuchi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2021122510440555400_onco13297-bib-0036","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hed.21433","article-title":"Clinicopathologic features as stronger prognostic factors than histology or grade in risk stratification of primary parotid malignancies","volume":"33","author":"Walvekar","year":"2011","journal-title":"Head Neck"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0841","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0841","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/7\/598\/41919331\/oncolo_25_7_598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/7\/598\/41919331\/oncolo_25_7_598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:46:38Z","timestamp":1640429198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/7\/598\/6443396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4,20]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0841","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,4,20]]}}}